AvantGen announces completion of first cancer therapeutic antibody discovery program for TRL

AvantGen collaborates with Tanabe Research Laboratories for successful completion of first cancer therapeutic antibody discovery program. AvantGen is accountable for producing novel antibodies to specified cancer targets making use of its proprietary human antibody yeast display technology platform for which it is liable for upfront payments and royalties associated with the products. Tanabe research labs have exclusive rights to commercialize antibodies discovered by the company.

Xiaomin Fan, Ph.D. founder and president of AvantGen, mentioned,”The platform utilizes advantageous technologies, including a robust yeast display system, large natural human antibody database and fully human antibody libraries, for the generation of antibodies to meet challenging design goals for therapeutic, diagnostic and research tool purposes.”

Roland Newman, Ph.D., chief scientific officer for TRL stated , “The therapeutic antibody discovery program conducted by AvantGen was highly collaborative and was accomplished faster than expected, without the need to further optimize the antibodies in order to meet TRL’s design goals.”